A novel series of 2-styryl-5-hydroxy-4-pyrone derivatives and analogues were designed and synthesized as H<sub>3</sub> receptor antagonism based multitarget-directed ligands (MTDLs) for AD therapy using pharmacophore-combine strategy. The 2-styryl-5-hydroxy-4-pyrone pharmacophore with metal ion chelation, antioxidation, and Aβ aggregation inhibition activities was employed as the "eastern part", and a typical phenoxyalkylamine moiety was used as "central ring + western part" of the H<sub>3</sub> receptor antagonist. The biological evaluation revealed that the majority of the target compounds demonstrated desirable multiple functions. The two most promising compounds 8a and 8b exhibited nanomolar IC<sub>50</sub> values on H<sub>3</sub> receptor antagonism, excellent metal ion chelating capability, more potent ABTS<sup>+</sup> scavenging activity than Trolox, efficient Aβ self-aggregation and Cu<sup>2+</sup>-induced aggregation inhibitory activities, as well as disaggregation activities against Aβ self/Cu<sup>2+</sup>-induced aggregation.